Regenerative Patch Technologies   Report issue

For profit Phase 2
Founded: Portola Valley CA United States (2011)
Status: No NME R&D (2011)

Organization Overview

First Clinical Trial
2015
NCT02590692
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Regenerative Patch Technologies, LLC

Active Ingredients

Drugs in Phase 2 Trials (1)

embryonic stem cell-derived rpe cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 2)

Geographic Atrophy (Phase 2)

Macular Degeneration (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1